DNA-synthesis rates and concentrations of bone marrow (BM) and peripheral blood (PB) progenitor cells were studied in 22 patients treated with recombinant human interleukin-3 (rhlL3) as part of a clinical phase 1/11 study. Recombinant hlL3 at doses of 60 to 500 pg/m2 was administered by subcutaneous bolus injection for 15 days to 13 patients with solid tumors and preserved hematopoietic function and to nine patients with bone marrow failure, including five with myelodysplastic syndromes. Following treatment with rhlL3, the percentage of actively cycling BM erythroid (BFU-E) and multilineage (CFU-GEMM) progenitors in patients with preserved hematopoietic function increased from 16% to 36% ( P < .05) and from 10% to 40% ( P < .01), respectively. The DNA-synthesis rates of early and late granulocyte macrophage progenitor cells increased from 11 % to 26% (CFU-GM day 14; P < .02) and from 13% to 30% (CFU-GM day 7; P < .05). There was an increase in BM cellularity from 37% to 58%. and of the myeloid to erythroid ratio from 1.4 to 3.2, while the concentration of marrow progenitors on a per cell basis was unchanged or slightly decreased. The frequencies of NTERLEUKIN 3 (IL3) belongs to a group of hematopoi-I etic colony-stimulating factors (CSFs) initially found to support the growth of hematopoietic progenitors as well as the functional activity of terminally differentiated cells in vitro.' Corresponding hematopoietic effects in vivo were subsequently demonstrated in preclinical animal models, implying a potential clinical utility of these growth factors in the treatment of hematopoietic failure or during increased hematopoietic Support for this prediction stems from several recent and ongoing clinical trials that indicate that biosynthetically produced (recombinant) granulocyte-CSF (G-CSF) and granulocyte-macrophage CSF (GM-CSF) are active stimulators of hematopoiesis in humans10.12-14 and may be effective in mitigating chemotherapy-induced or ameliorating cytopenias in bone marrow failure of diverse etiology, eg congenital and acquired n e u t r~p e n i a , '~~~~ myelodysplastic syndrome^,^^-^^ and aplastic anemia.2z.25 However, CSFs such as GM-CSF have not been universally effective in stimulating hematopoiesis, eg in congenital agranulocytosis.26 severe aplastic anemia or MDS,25,27 possibly due to a lack of activity on sufficiently blast cells in the BM were unchanged. Mean levels of PB CFU-GM day 14 and CFU-GEMM were 100% and 72% above baseline values after 7 days of rhlL3 but only 25% and 28% above initial levels at the end of treatment.
in 21 of 22 patients with a peak response after a median of 13 days of rhlL3. While a small increase in reticulocytes was not accompanied by an elevation of the hemoglobin or hematocrit, platelet counts increased by 50% in patients with preserved marrow function. Thus, rhlL3 induces a multilineage response in vivo, apparently by stimulating proliferation of multipotential and lineage-restricted progenitors. It remains to be determined whether this is due to direct or indirect effects on the progenitor cells. 0 1990 by The American Society of Hematology.
immature progenitor cells or continuing immune-mediated suppression. Current evidence suggests that the T-cellderived lymphokine IL3 stimulates proliferation and differentiation of ontogenetically earlier stem and progenitor cells than the other currently known CSFs. In order to assess the pharmacokinetics, hematologic effects and toxicity of recombinant human IL3 (rhIL3) and its effects on hematopoietic progenitor populations, we recently initiated a phase 1/11 clinical trial of rhIL3 in patients with solid tumors or bone marrow failure." In the present report, we demonstrate the changes in cycling status and concentration of marrow and blood progenitors and the associated changes in bone marrow and hematologic parameters in 22 patients receiving rhIL3 during a 15 day treatment cycle.
MATERIALS AND METHODS
A detailed description of the design and protocol of this phase 1/11 clinical trial is presented elsewhere.28 Briefly, patients with a histologically proven malignancy refractory to standard therapy or with transfusion-dependent bone marrow failure were entered into the study. Eligibility criteria included a life expectancy of greater than 3 months and a Karnofsky score of more than 50%. The study was approved by the local ethics committee, all patients gave informed written consent prior to initiation of treatment. Clinical characteristics of the 22 patients included in the present report are summarized in Table 1 . Underlying diseases were solid tumors with no evidence of bone marrow involvement or hematopoietic insufficiency in 13 patients, metastatic carcinoma of the breast and centrocytic lymphoma infiltrating the bone marrow in one patient each, Hodgkin's disease and secondary hematopoietic failure following polychemotherapy in one patient, cyclic thrombocytopenia in one patient, and a myelodysplastic syndrome (MDS) in five patients. Three of the latter had a deletion of the long arm of chromosome 5 (5q-syndrome), one had refractory anemia (RA) and one presented with an atypical MDS with increased marrow fiber content. All five patients with MDS required frequent RBC and/or platelet transfusions that had to be continued throughout rhIL3 therapy in three patients. The mean time interval Study design andpatient characteristics. 'Criteria for normal hematopoietic function are normal platelet and erythrocyte counts and a normal WBC and differential in conjunction with 1) a normal bone marrow morphology as judged by a bone marrow aspirate and/or biopsy (n = 9) and 2) a normal bone scan in two patients (5 and 1 1) in whom bone marrow morphology was not available.
'ADR denotes Adriamycin, VCR vincristin, V8L vinblastine, 4-Epi epirubicin, MTX methotrexate, DDP cisplatin, PRO procarbazine, Clb chlorambucil, 5FU 5-Fluorouracil, CTX cytoxan, BLEO bleomycin.
.Interval between final administration of previous therapy and initiation of rhlL3; RBC transfusions were given throughout IL3 therapy.
between the last preceding specific antineoplastic therapy and rhIL3 administration was 16 weeks (range 2.5 to 36 weeks). Treatment with rhIL3 was initiated 2.5 weeks after completion of lithium therapy in one patient with cyclic thrombocytopenia, 2.5 weeks after 5-fluorouracil (5FU) treatment in one patient with pancreatic carcinoma whose WBC had remained unchanged following 5-FU, and 3.5 weeks following interferon-a treatment (3 x IO6 units three times per week) in a patient with 5q-syndrome. Three patients with normal hematopoietic function and three patients with MDS had received no previous cytokine or chemotherapy. Recombinant human interleukin 3 was administered by daily subcutaneous bolus injection at doses ranging from 60 to 500 pg/m2 for 15 days. Further dose escalation was stopped at 500 pg/m2 because of toxicity considered unacceptable for prolonged therapy (bone pain, chills and fever, WHO grade IV) in two patients (not included in this report) and increased thrombocytopenia in two patients with aplastic anemia and MDS, respectively. Recombinant IL3 and other colony stimulating factors. Recombinant human IL3 was provided by Immunex/Behringwerke AG (Seattle, WA/Marburg, FRG). Its cDNA was cloned from human peripheral blood lymphocytes and expressed in yeast as previously described. 29 The secreted and purified molecule had a molecular weight of 14 to 16 Kd and a specific activity of approximately 1 x lo7 units/mg protein as determined in a bone marrow proliferation assay. The clinical preparation was formulated in lyophylized form to be reconstituted with sterile water. Endotoxin content was < lOpg/mg protein in the limulus amebocyte lysate assay. Sterility, general safety and purity studies met the Food and Drug Administration (FDA) standards. Recombinant human G-CSF and GM-CSF used in the in vitro assays was purified by Immunex Corp (Seattle, WA) as described29 and kindly provided by Dr Krumwieh (Behringwerke AG, Marburg, FRG). Recombinant human erythropoietin (EPO) was a generous gift from Boehringer Mannheim AG, Mannheim, FRG. Peripheral blood was collected within one day prior to rhIL3 administration, after seven days of treatment and one day after the last dose of rhIL3 (day 16). Bone marrow (BM) aspirates and trephine biopsies from the posterior iliac crest were obtained immediately before and on the first day following the treatment cycle. Mononuclear cells (MNC) were separated by centrifugation over Ficoll-Hypaque and used either directly in progenitor cell assays or cryopreserved in 10% fetal calf serum (FCS), 10% DMSO at a controlled rate of l0C per minute using a Cryoson programmable cryopreservation apparatus.
Bone marrow smears were evaluated after staining with May-Grunwald-Giemsa (Pappenheim) stain. Biopsies were decalcified, and paraffin-embedded sections were stained with hematoxylin-eosin, Giemsa and Gomori's silver stain for reticulin fibers. Examination of the aspirates and biopsy specimens was performed under code by two independent observers. Bone Blood and bone marrow samples and cellpreparation.
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For personal use only. on September 13, 2017. by guest www.bloodjournal.org From marrow cellularity was assessed, by a point counting planimetric method using a 100-point graticule at a magnification of 160x. The relative amounts of hematopoietic tissue, fat cells, bone and vascular structures were calculated from the mean point counts obtained in 15 fields for each biopsy specimen.
Clonogenic assays for burst-forming units-erythroid (BFU-E) and multilineage colony-forming cells (CFU-GEMM) were performed in methylcellulose essentially as described," granulocyte-macrophage colony forming cells (CFU-GM) were cultured in 0.3% agar. Low-density bone marrow (LDBM) cells were plated at 5 x lo4 cells/mL, peripheral blood mononuclear cells at 2 x IO5 cells/mL in quadruplicate 1 mL aliquots in 35 mm dishes and incubated at 37OC in a fully humidified atmosphere of 5% CO, in air. Recombinant human GM-CSF, G-CSF and IL3 were incorporated at plateau concentrations (10 ng/mL), previously determined to have maximal colony-stimulating activity in our hands (unpublished observation); EPO (2 U/mL) was added to methylcellulose cultures to facilitate development of BFU-E and CFU-GEMM. Erythroid and mixed colonies were scored on day 14; CFU-GM on days 7 and 14 of culture.
To compare the number of blood progenitor cells per unit volume during treatment with rhIL3, the following equation was used: CFU/mL blood = (CFU/I06 MNC) x leukocytes/mL blood x (percent MNC in the differentia1/100).
The tritiated thymidine suicide assay was used as described3' with slight modifications to determine the percentage of progenitor cells in DNA-synthesis (S-phase). Briefly, LDBM cells were suspended in Iscove's modified Dulbeccos medium (IMDM)/lO% FCS at 1 x IO6 cells/mL and duplicate cultures incubated with tritiated thymidine (200 pCi/mL, 40 Ci/mmol/L specific activity, Amersham) for 30 minutes at 37OC. 'H-TdR incorporation was stopped by adding 0.5 mg/mL unlabeled thymidine followed by three washes in ice-cold medium. Control cultures were likewise performed in duplicate. Following pulse treatment with 'H-Tdr or mock, cells from each culture tube were incorporated in clonogenic assays performed in quadruplicate one mL aliquots as described above. For convenience, an arithmetically negative DNAsynthesis rate was considered as zero % progenitors in cell cycle.
The Wilcoxon rank sum test for paired data and Student's t-test for paired data were used for statistical analysis.
RESULTS
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Cell cycle rates and frequencies of bone marrow progenitors. The proliferative rate and concentration of BM progenitors were assessed before and immediately following 15 days of treatment with 60 to 500 pg/m2 rhIL3 in nine patients with normal hematopoietic function and no evidence of neoplastic bone marrow involvement; in one patient with cyclic thrombocytopenia; in one patient with centrocytic lymphoma infiltrating the bone marrow; and in one patient with 5q-syndrome ( Table 2 ). The frequency of bone marrow progenitor cells was determined in a tenth patient with intact hematopoiesis in whom too few cells were available for cell cycle analysis. In nine hematopoietically normal patients, the percentage of BFU-E and CFU-GEMM in S-phase (mean f SD) increased from 16% 21% (range 0% to 68%) and 10% f 18.6% (range 0% to 57%) to 36% k 12% (range 16% to 56%) and 40% f 22% (range 0% to 63%), respectively (P < .05 and P < .01, Wilcoxon test). The mean cycling rate of day 14 CFU-GM increased from 10.6% f 10% (range 0% to 29%) to 26% + 10% (range 8% to 38%) (P < .02). The DNA-synthesis rate of BFU-E increased in eight and decreased in one patient, while the cycling rates of both CFU-GEMM and day 14 CFU-GM increased in seven of the nine patients and were essentially unchanged in the remaining hematopoietically normal patients (no. 1 and 2 and 1 and 10, respectively) ( Table 2 ). The percentage of actively cycling day 7 CFU-GM increased in five of six patients and was essentially unchanged in one case; mean cycling rates were 13% f 8% (range 0% to 21%) before and 30.5% f 8%
(range 21% to 39%) after rhIL3 (P < .05, Wilcoxon test). In one patient (no. 1, Table 2 ) with an exceptionally high percentage of BFU-E, CFU-GEMM and day 14 CFU-GM in DNA-synthesis at baseline (68%, 57% and 29%, respectively), the cycling rate of BFU-E decreased and that of CFU-GEMM and day 14 CFU-GM showed no significant change following treatment with 60 pg/m2 rhIL3. No increase in the cycling rate of erythroid, multilineage or myelomonocytic progenitors was seen in two patients with cyclic thrombocytopenia and bone marrow infiltration by lymphoma, respectively (no. 14 and 16), both of whom received 60 pg rhIL3/m2. In one patient with 5q-syndrome (no. 18), the percentage of early CFU-GM in S-phase increased from 14% pre-treatment to 36% following 15 days of 250 pg rhIL3/m2; CFU-GEMM and BFU-E were undetectable both before and after rhIL3 treatment ( Table 2) .
In contrast to the cell cycle effects of rhIL3, changes in the frequencies of BM progenitor cells were quite variable even in the group of patients with normal hematopoietic function (Table 2 , n = 10): the incidence of BFU-E decreased in six, increased in two, and remained unchanged in two of the ten patients. Their concentration, expressed as colonies (mean + SD)/1 x lo5 low-density cells before and after IL3, decreased from 82 k 52 (range 18 to 179) to 57 27 (range 25 to 105). CFU-GEMM decreased in three, increased in three, and remained essentially unchanged in four of ten patients with a mean (+SD) incidence (1 x lo5 cells) of 17 f 17 (range 2 to 53) before and 13 9 (range 3 to 30) after rhIL3. Similarly, the concentration of day 14 CFU-GM decreased in six and increased in four of ten patients; the mean incidence was unchanged a t 150 * 81/1 x lo5 cells before and 145 * 75/1 x lo5 cells after rhIL3. The concentration of day 7 CFU-GM decreased in 5 of seven cases (268 + 133/1 x lo5 cells and 159 + 81/1 x lo5 cells before and after treatment, respectively). In the majority of cases, the incidence of the different progenitor types changed in a concordant manner; one exception is a patient with normal hematopoiesis (no. 12, Table 2) in whom increases in the concentration of CFU-GEMM and day 14 CFU-GM were accompanied by a decrease in the incidence of BFU-E.
Bone marrow cellularity was quantitated by planimetric analysis of bone marrow biopsies obtained from ten patients (no. 2, 3, 6, 8, 12, 13, 15, 16, 18, 19; Table 1 ) before and after 15 days of treatment with rhIL3. The mean (kSD) cellularity increased from 37% 16% to 58% 16% overall (P < .01, Wilcoxon test), and from 36% 17% to 64% + 5% in six patients with normal hematopoiesis (no. 2, 3, 8, 12, 13; Table 1 ). In five of these patients, the cellularity increased; in one, it remained essentially unchanged (58% and 57%) (no. 6, Table 1 ). Evaluation of marrow biopsies from four patients with secondary bone
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For marrow failure (no. 15 and 16) and MDS (no. 18 and 19) revealed an 56% k 9% increase in cellularity above baseline following rhIL3. An enhancement of marrow cellularity by rhIL3 administration was also evident in bone marrow aspirates from nine of eleven patients with normal hematopoietic function (no. 1, 2, 3, 4, 8, 9, 10, 12, 13; Table 1 ). This resulted primarily from a stimulation of myelopoiesis with a shift to the left and a pronounced eosinophilia. The median myeloid to erythroid ratio was 1.43: 1 before and 3.2: 1 after treatment. Promyelocytes plus myelocytes increased from 12.7% f 1.3% to 19.4% + 1.5% of total marrow cells (P < .01, Wilcoxon test; P < .0025, Student's t-test), and eosinophils increased from 3.9% f 0.7% to 12% f 1.3% (P < .01, Wilcoxon test; P < .0005, Student's t-test) (Fig 1) .
There was no significant change in the percentage of metamyelocytes and band forms (23.4% f 2% versus 22.2% k 1.4%), segmented neutrophils (12.3% f 1.8% versus 11.4% + 2%) or basophils (0.3% k 0.14% versus 0.5% 0.2%). Lymphocytes and erythroid precursors decreased from 11.3% f 2.2% to 6.8% k 1.3% (P < .01, Wilcoxon test) and from 32% f 2.9% to 23.6% A 2% (P < .05, Wilcoxon test), respectively.
Myeloblasts remained undetectable after IL3-treatment, and the percentage of monocytes and plasma cells likewise was essentially unchanged. A similar response pattern was seen in three patients with 5q-syndrome; however, in these patients the rise in eosinophils was accompanied by a conspicuous increase in basophils from 2.3% 5 1% to 8.7% + 2.7%. The percentage of other mature myeloid elements or of myeloblasts did not change significantly.
The frequencies of circulating progenitor cell subsets were assessed in maximally stimulated clonogenic assays as described in Methods. Table 3 depicts the results for 12 patients with intact hematopoietic function. Following one week of rhIL3 treatment, day 14 CFU-GM were increased in eight and decreased in three patients with an increase to 200% f 148% (mean SD) of baseline values. CFU-GEMM were increased in seven, decreased in four, and unchanged in one patient with a mean of 172% f 170% of day 0 levels; BFU-E were elevated above starting levels in three and decreased in nine patients, with a mean of 104% + 112% of day 0 values.
The frequency of circulating progenitor cells detected immediately after completion of rhIL3 treatment was generally lower than after the first week of treatment (Table 3) . Numbers of day 14 CFU-GM and CFU-GEMM per volume of blood were 72% and 45% above pre-treatment values
Concentration of blood progenitor cells.
For respectively, whereas the number of BFU-E decreased by 33%. These changes were not statistically significant. Overall, the interpatient variability of the results was unrelated to the dose level of rhIL3.
In three patients with secondary hemopoietic failure and/or tumor infiltration of the bone marrow (no. 15, 16, 17; Table 4 ), the level of detectable circulating progenitor cells decreased during rhIL3 administration, except for an increased number of BFU-E in one patient after one week of treatment. In all five patients with MDS, circulating BFU-E and CFU-GEMM were either absent or present only in extremely low numbers before treatment and were not significantly increased after rhIL3 administration ( Table 4) For personal use only. on September 13, 2017. by guest www.bloodjournal.org From 764/pL initially to 9,300 f 2,207/pL (mean 2 SD) after 15 days in three of four patients with altered hematopoietic function (no. 14, 16, 17; Table l) , and from 3,540 * 416/pL to 8,740 f 4,308/pL in all five patients with MDS. The increase in leukocyte counts in the five MDS patients was due to elevated neutrophil and eosinophil levels similar to those in the other patient groups; a pronounced increase in circulating basophils, (from 46 f 56/pL to 585 f 74/pL), was seen in only the three patients with 5q-syndrome. Following discontinuation of rhIL3, the WBC gradually decreased towards baseline levels. Although the reticulocyte counts in the 13 hematopoietically normal patients increased slightly from 1.06 f 0.36 x 106/pL to 1.48 0.64 x 106/pL after 15 days, this was not associated with a significant increase in either hemoglobin or hematocrit, and transfusion requirements in two patients with hematopoietic failure (no. 18 and 20, Table 1 ) temporarily increased. Platelets increased in 12 of 13 patients with normal hematopoietic function from 304,700 f 105,50O/pL to a maximum of 452,800 * 119,500 pL (P -= .01) after a median time of 15 days (range 11 to 26 days). Overall, treatment with rhIL3 was well tolerated, mild constitutional symptoms being the predominant side effects.
DISCUSSION
Based on the well-established capacity of interleukin 3 to stimulate multiple hematopoietic lineages in ~itro~'.'~ and on initial results from animal st~dies,7,~*~~~'"' it was anticipated that rhIL3 would be a broad acting hematopoietic stimulator in humans. Our evidence that the administration of pharmacologic doses of rhIL3 induces a pronounced increase in the DNA synthesis rate of CFU-GEMM, BFU-E and CFU-GM is in accordance with this expectation and demonstrates that rhIL3 retains its multilineage activity in vivo. Similar effects on the cycling status of BFU-E and CFU-GM have been observed previously following the clinical administration of G M -C S P ' V~~ and EP0. 43 Although IL3 has been shown to act on highly purified progenitor populations in vitro, indicating its capacity to stimulate progenitor cells growth directly, we are not able to discriminate between directly and indirectly mediated hematopoietic effects in vivo. Nevertheless, treatment with rhIL3 was associated with increases in bone marrow cellularity and elevated peripheral WBC counts. The magnitude and the kinetics of the response differed from those observed with G-CSF'3*'4744 or GM-CSF'2,45 and were characterized by a more moderate elevation of leukocyte numbers and a more delayed onset after approximately seven to nine treatment days. These data are consistent with a model in which rhIL3 stimulates hematopoiesis by enhancing stem and progenitor cell proliferation. Despite a comparable stimulation of erythroid, multilineage and myeloid progenitor cell cycling rates, the exogenous administration of rhIL3 enhanced myelopoiesis to a larger degree than did erythropoiesis as judged by an increased mye1oid:erythroid ratio in bone marrow sections and completely failed to enhance hemoglobin levels, hematocrit or erythrocyte numbers. A similar discrepancy between the in vivo effects on erythropoiesis and on myelopoiesis was reported for rhGM-CSF in a recent clinical in which a declining responsiveness of more mature erythroid precursors to in vivo stimulation by GM-CSF was reported. In vitro, IL3 and GM-CSF do not support complete hematopoietic differentiation in the absence of late-acting hematopoietins or accessory ~e l l s .~~-~* It can be inferred from the cell cycle data in conjunction with the clinical response to rhIL3 that endogenous late-acting granulopoietic activities are present in sufficient concentrations to result in an elevated total leukocyte count upon in vivo administration of rhIL3 alone, whereas an augmentation of erythrocyte production by rhIL3 requires higher levels of activity supporting terminal erythroid maturation. In a clinical setting, the concomitant administration of erythropoietin and rhIL3 may be the most promising combination to achieve this effect.
Analogous to preclinical and clinical trials of recombinant G-CSFI4 and GM-CSF," the frequencies of bone marrow progenitors were unchanged or reduced following treatment. As dilution of progenitors by the expanded number of more mature precursor and end-stage cells present in the consistently more cellular bone marrow is a likely explanation, the total BM progenitor cell content may well have expanded during treatment. Redistribution of progenitors is another possibility. Except for early CFU-GM and CFU-GEMM, For personal use only. on September 13, 2017. by guest www.bloodjournal.org From 1500 OlTMANN ET AL when assayed after 7 days of rhIL3 treatment, circulating progenitor cell levels were not consistently elevated; rather, the number of BFU-E, and CFU-GEMM after 15 treatment days, per unit volume of blood decreased in the majority of patients, whereas only small increases were observed in the remaining patients. This contrasts with observations from clinical studies of G-CSF, GM-CSF and EPO and a recent study of IL3 in primates, in which considerable elevations of circulating progenitor cells were o b~e r v e d . '~.~~-~~-~' However, more variable responses during treatment with GM-CSF have also been observed,4' and murine studies indicate that species differences may account for some of these discrepancies. These may be partly due to distinct patterns of progenitor cell compartmentalization within different hematopoietic organs during treatment with IL3.38.52 These findings raise some doubts that IL3 administration will facilitate procurement of larger quantities of peripheral blood stem cells for use in autologous bone marrow transplantation, as has been suggested for G-CSF and GM-CSF"-'4; however, the progenitor cells assayed in this study are known not to be responsible for reconstitution of hematopoiesis. Several details of the changes of cellular composition of the bone marrow during treatment deserve attention. The increased cellularity reflected an increase primarily of promyelocytes, myelocytes and eosinophils; the percentage of blast cells did not increase either in patients with normal bone marrow or those with MDS. In several recent studies, a stimulation of blast cells by GM-CSF was seen predominantly in patients with high initial blast cell c o~n t s .~'~~~ Consequently, the latter results can not be extrapolated to MDS in general. An increase of eosinophils and basophils had been anticipated from in vitro in this clinical study a pronounced eosinophilia, but no significant change in basophil numbers, was seen in patients without a primary hematologic disorder. It is presently unclear why elevated basophil counts were seen only in the patients with MDS; possibly, higher levels of basophil maturation activities were present in the patients examined. This lack of a substantial basophilia should in fact be advantageous as a reduced risk of allergic reactions can be anticipated. Indeed, urticarial reactions have been observed in primates treated with IL3.5' In the present study, no significant allergic reactions were associated with the elevated eosinophil counts. In conclusion, this report demonstrates that rhIL3 has the capacity to enhance hematopoiesis in humans and appears to do so, at least in part, by directly or indirectly stimulating active cycling of multipotential and lineage-restricted progenitor cells. In accordance with its known in vitro and in vivo activities, rhIL3 is likely to have potential clinical utility in bone marrow failure states and should be even more effective in combination with other CSFs acting at later stages of differentiation. For personal use only. on September 13, 2017. by guest www.bloodjournal.org From
